Dojolvi (triheptanoin) NDC 69794-050

NDC codes

FDA NDC Directory

Product NDC (as listed)69794-050Labeler and product segments. Claims need a package NDC.

Product NDC at billing width69794-0050Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
69794-050-50	69794005050	1 BOTTLE, GLASS in 1 CARTON (69794-050-50) / 500 mL in 1 BOTTLE, GLASSMarketed from Jul 1, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dojolvi
Generic name (nonproprietary): triheptanoin
Active ingredients: Triheptanoin — .96 g/mL
Dosage form: Liquid
Route: Oral
Labeler: Ultragenyx Pharmaceutical Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 213687
Marketing start: Jul 1, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Triglycerides (Chemical structure)
Identifiers: Product ID 69794-050_a89d49c1-092a-4911-bbcc-611479f4c444SPL ID a89d49c1-092a-4911-bbcc-611479f4c444SPL set ID 4cfeb8bd-143e-4dd7-bc34-b0bcda02460dRxCUI 2383555, 2383561UNII 2P6O7CFW5K
Pharmacologic class: Medium-chain Triglyceride

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N469794005050 followed by a unit qualifier and the quantity

Package 69794-0050-50. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 10, 2025.

Indications (excerpt from the label)

DOJOLVI is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). DOJOLVI is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)